NCT04619914View on ClinicalTrials.gov

the Effect of Clomiphene Citrate Plus Estradiol Valerate Versus Letrozole on Endometrial Thickness and Pregnancy Rate in Infertile Women

NACompletedINTERVENTIONAL
Enrollment

160

Participants

Timeline

Start Date

March 1, 2019

Primary Completion Date

July 1, 2019

Study Completion Date

August 10, 2019

Conditions
Endometrial ThicknessPregnancy Rate
Interventions
DRUG

Clomid; Aventis pharma S.AE, Global Napi pharmaceuticals, Cairo, Egypt

CLOMID (clomiphene citrate tablets USP) is an orally administered, nonsteroidal, ovulatory stimulant designated chemically as 2-\[p-(2-chloro-1,2-diphenylvinyl)phenoxy\] triethylamine citrate (1:1)

DRUG

letrozole (Femara; Novartis pharma AG, Basle, Switzerland)

Letrozole, or CGS 20267, is an oral non-steroidal type II aromatase inhibitor. It is a third generation aromatase inhibitor like exemestane and anastrozole, meaning it does not significantly affect cortisol, aldosterone, and thyroxine.

Trial Locations (1)

23451

Faculty of Medicine, Zagazig

All Listed Sponsors
lead

Laylay Mohammed Khalleefah Alhibshi

OTHER_GOV

NCT04619914 - the Effect of Clomiphene Citrate Plus Estradiol Valerate Versus Letrozole on Endometrial Thickness and Pregnancy Rate in Infertile Women | Biotech Hunter | Biotech Hunter